Dysregulated Expression and Methylation Analysis Identified TLX1NB as a Novel Recurrence Marker in Low-Grade Gliomas

Hongzhou Duan; Zuozhen Yang; Chen Li; Jiayong Zhang; Shengli Shen; Changwei Yuan; Yingjin Wang

doi:10.1155/2020/5069204

Dysregulated Expression and Methylation Analysis Identified TLX1NB as a Novel Recurrence Marker in Low-Grade Gliomas

Int J Genomics. 2020 Oct 12:2020:5069204. doi: 10.1155/2020/5069204. eCollection 2020.

Authors

Hongzhou Duan¹, Zuozhen Yang², Chen Li³, Jiayong Zhang¹, Shengli Shen¹, Changwei Yuan¹, Yingjin Wang¹

Affiliations

¹ Department of Neurosurgery, Peking University First Hospital, Beijing 100034, China.
² MOE Laboratory of Biosystem Homeostasis and Protection, College of Life Sciences, Zhejiang University, Hangzhou, Zhejiang 310058, China.
³ Department of Pediatric Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China.

Abstract

Low-grade gliomas (LGGs) are the most common CNS tumors, and the main therapy for LGGs is complete surgical resection, due to its curative effect. However, LGG recurrence occurs frequently. Biomarkers play a crucial role in evaluating the recurrence and prognosis of LGGs. Numerous studies have focused on LGG prognosis. However, the multiomics research investigating the roles played by gene methylation and expression in LGG recurrence remains limited. In this study, we integrated the TCGA and GEO datasets, analyzing RNA and methylation data for recurrence (R) and nonrecurrence (NR) groups. We found a low expression of TLX1NB and high methylation in recurrence patients. Low expression of TLX1NB is associated with poor survival (OS: p = 0.04). The expression of TLX1NB is likely to play a role in the prognosis of LGG. Therefore, TLX1NB may represent an alternative early biomarker for the recurrence of low-grade gliomas.